NCT03956550: A reported trial by Regeneron Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03956550 |
|---|---|
| Title | A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 21, 2019 |
| Completion date | May 1, 2020 |
| Required reporting date | May 1, 2021, midnight |
| Actual reporting date | April 28, 2021 |
| Date last checked at ClinicalTrials.gov | March 30, 2026 |
| Days late | None |